AKT1 and lung cancer: Specifically, both PTX3 deglycosylation and PTX3 knockdown via AKT/NF-κB signaling inhibition have been shown to suppress tumor growth, enhancing the susceptibility of lung cancer cells to cisplatin treatment (80, 81).